Aardvark (AARD) Director Jeffrey Chi Receives 44,964-Share Award

What Happened

• Jeffrey Chi, a director of Aardvark Therapeutics (AARD), was granted a derivative equity award covering 44,964 shares on August 14, 2026. The Form 4 reports an acquisition price of $0 (derivative award), which indicates an equity/option grant rather than an open-market purchase.

Key Details

• Transaction date: 2026-08-14; Form 4 filed: 2026-08-21 (appears filed late relative to the 2-business-day rule).
• Instrument: Derivative equity award (44,964 shares) reported as acquired at $0.00.
• Shares owned after transaction: not specified in the filing.
• Footnote: The award vests in full on the earlier of (i) August 14, 2027, or (ii) immediately prior to the company’s next annual meeting of stockholders following the grant date, subject to continuous service through the vesting date.
• No sale or cashless exercise reported — this is a grant/award, not a disposition or market trade.

Context

• This filing documents a typical director compensation award rather than a purchase or sale. Such grants are commonly used to compensate board members and do not necessarily indicate the director’s view of the stock. The late filing reduces prompt transparency but does not change the nature of the award.